CymaBay Therapeutics

General Information

Company Name

Founded Year

1991

Location (Offices)

Newark, United States +1

Founders / Decision Makers

Number of Employees

Industries

Biopharma, Biotechnology, Pharmaceutical

Funding Stage

Post Ipo Equity

Social Media

CymaBay Therapeutics - Company Profile

CymaBay Therapeutics is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients with liver diseases. The company is focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need. Their lead candidate, Seladelpar, is a potent, selective, orally active PPARδ agonist in development for the treatment of patients with the autoimmune liver disease, primary biliary cholangitis (PBC). In addition to Seladelpar, CymaBay Therapeutics' pipeline includes additional investigational products and lead candidates for liver and other chronic diseases. Founded in 1991 and headquartered in the United States, CymaBay Therapeutics received a $258.70M Post-IPO Equity investment on 11 September 2023. With its focus on developing therapies for high unmet medical needs, CymaBay Therapeutics presents an intriguing prospect for potential venture capital investors.

Taxonomy: biopharmaceutical company, clinical-stage, liver diseases, autoimmune liver disease, therapies, PPARδ agonist, primary biliary cholangitis, investigational products, chronic diseases, San Francisco Bay Area, proprietary medicines, gout, uric acid, Phase 2 studies, metabolic disease

Funding Rounds & Investors of CymaBay Therapeutics (15)

View All

Funding Stage	Amount	No. Investors	Date
Post-IPO Equity	$258.70M	-	11 Sep 2023
Post-IPO Equity	$85.00M	-	24 Jan 2023
Post-IPO Debt	$75.00M	-	18 Nov 2021
Post-IPO Debt	$100.00M	1	02 Aug 2021
Post-IPO Equity	$144.00M	-	06 Feb 2018